Medical Research and Development teams have carried out breakthrough and enduring research over the past two decades. Finally FY2014 has emerged as the most productive year in all respects in the development pipeline. The FDA has taken into consideration many applicants and finally gave a green flag to a plethora of drug compounds, as many as 41. The gamut of drugs green flagged comprises ones that would fight diseases, viruses, skin issues and cancer.
Invariably, 2014 was a key year of substantial drug launches. This provides an exquisite premise for 2015 to jumpstart. This year is slated to bring about a myriad of exquisite changes and new treatments pertaining to rampant fluctuations of cholesterol, occasions of heart failures and cystic fibrosis. There are four top notch drugs that might seek limelight and gain approval over the next few months in FY2015 and garner annual sales exceeding $1 Billion.
Sanofi SA (ADR) (NYSE:SNY) may partner with Amgen, Inc. (NASDAQ:AMGN) or the famous Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and develop a first class drug that would lower cholesterol. Termed PCSK9 inhibitors, the drug would function in stopping certain protein that removes up to two-thirds and stops secretion of LDL or bad cholesterol. The main reason it is drawing flak is the hyped price level that ranges annually between $7,000 and $12,000.
Novartis AG (ADR) (NYSE:NVS) has plans to unveil LCZ696 in all the states of the US for people who suffer from chronic heart disease. This drug can reduce death concerns by around 20%, thus minimalizing hospitalizations.
Novartis may come up, with a distinctively innovative way to treat skin debilitating psoriasis with Cosentyx that blocks the inflammation causing protein. Incidentally, 75% of overall symptoms tend to reduce on using Cosentyx.
Handling Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has emerged as a manufacturer of Kalydeco – the drug that has been around in small partitions, and when paired or combined, with VX-809 can be deftly used to refrain from inviting some fatal and rare disorder pertaining to human genetics.
Currently, overall earnings in 2015 may rise past 33% and propel further by 19% in 2016.